Research Topics
Species | Nicholas J VogelzangSummaryAffiliation: Nevada Cancer Institute Country: USA Publications
| Collaborators
|
Detail Information
Publications
Standard therapy for the treatment of malignant pleural mesotheliomaNicholas J Vogelzang
Nevada Cancer Institute, Las Vegas, NV 89135, USA
Lung Cancer 50:S23-4. 2005..This doublet-based chemotherapy regimen is now the standard therapy for the first-line treatment of MPM...- Chemotherapy for malignant pleural mesotheliomaNicholas J Vogelzang
Nevada Cancer Institute, Las Vegas, Nevada 89135, USA
Lancet 371:1640-2. 2008 
Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancerJoseph D Khoury
Dept of Pathology, Nevada Cancer Institute, One Breakthrough Way, Las Vegas, NV 89135, USA
Am J Clin Pathol 134:964-9. 2010..024). Increases in quantitative D-dimer levels correlate with progressive disease better than CTC counts in patients with refractory prostate cancer...- Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancerJason C Gonzales
Department of Laboratory Medicine, Nevada Cancer Institute, Las Vegas, 89135, USA
Clin Genitourin Cancer 9:39-45. 2011..Furthermore, miR-141 demonstrated high correlation with changes of the other biomarkers... - Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancerOscar B Goodman
Department of Clinical Oncology, Nevada Cancer Institute, Las Vegas, 89135, USA
Clin Genitourin Cancer 9:31-8. 2011..Multivariate analysis revealed baseline CTC as the only independent predictor of progression to CRPC. These data suggest that baseline CTC may identify those unlikely to benefit from ADT... - Conclusion and future directionsWolfram E Samlowski
Section of Melanoma, Renal Cancer and Immunotherapy, Nevada Cancer Institute, Las Vegas, NV 89135, USA
Cancer J 14:330-2. 2008..This issue of The Cancer Journal has been devoted to reviewing clinical progress in the treatment of metastatic renal cancer, with an eye toward current needs and the likely future directions of the field... - New agents in the management of advanced mesotheliomaNicholas J Vogelzang
Nevada Cancer Institute, Las Vegas, NV 89135, USA
Semin Oncol 32:336-50. 2005..Together with the newer drugs, rapidly emerging from the laboratory to be applied in the clinic, we have the hope of making further advances in the struggle against this disease... - Emerging drugs for the treatment of metastatic renal cancerWolfram E Samlowski
Section of Melanoma, Renal Cancer and Immunotherapy Nevada Cancer Institute, One Breakthrough Way, Las Vegas, NV 89135, USA
Expert Opin Emerg Drugs 12:605-18. 2007..These agents are rapidly progressing through clinical testing in renal cancer and in other malignancies. This paper overviews the status of these investigational agents and anticipates areas of future research and development... - Outcomes and prognosis in advanced renal cell carcinomaMatthew D Galsky
Genitourinary Oncology Program, US Oncology Research, Las Vegas, Nevada, USA
Expert Rev Anticancer Ther 7:839-45. 2007..This review will focus on studies that define the outcome and prognosis in advanced renal cell carcinoma... - Signal-transduction inhibitors in renal cell carcinomaNicholas J Vogelzang
Nevada Cancer Institute, University of Nevada School of Medicine, Las Vegas, NV, USA
BJU Int 99:1289-95. 2007 - Management of renal cancer in the tyrosine kinase inhibitor era: a view from 3 years onWolfram E Samlowski
Section of Melanoma, Renal Cancer and Immunotherapy, The Nevada Cancer Institute, Las Vegas, NV 89135, USA
BJU Int 102:162-5. 2008..This brief review is intended to overview recent developments, and to identify advances that are likely to influence treatment decisions... - Dramatically elevated circulating tumor cell numbers in a patient with small cell neuroendocrine carcinoma of the prostateFanny Chan
Department of Medical Oncology, Nevada Cancer Institute, Las Vegas, NV 89135, USA
Arch Pathol Lab Med 134:120-3. 2010.... - Multimodality therapy in mesothelioma: role of chemotherapyNicholas J Vogelzang
Nevada Cancer Institute, 10, 000 West Charleston Boulevard, Suite 260, Las Vegas, NV 89135, USA
Thorac Surg Clin 14:531-42. 2004.... - Promising systemic therapy for renal cell carcinomaMatthew M Cooney
Nevada Cancer Institute, University of Nevada School of Medicine, Las Vegas, NV 89135, USA
Curr Treat Options Oncol 6:357-65. 2005..A review of the preclinical and early clinical development of some of these novel compounds will be discussed... - Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factorsOscar B Goodman
Department of Clinical Oncology, Nevada Cancer Institute, One Breakthrough Way, Las Vegas, Nevada 89135, USA
Cancer Epidemiol Biomarkers Prev 18:1904-13. 2009..Patients received ongoing medical oncologic follow-up for up to 26 months, and overall survival status was documented... - Treatment options in metastatic renal carcinoma: an embarrassment of richesNicholas J Vogelzang
J Clin Oncol 24:1-3. 2006 - Novel agents for the treatment of advanced kidney cancerMatthew M Cooney
Case Comprehensive Cancer Center, Cleveland, OH 44106, USA
Clin Adv Hematol Oncol 2:664-70. 2004..These compounds include antiangiogenic agents, raf kinase pathway inhibitors, and novel antimicrotubule agents. This review discusses some of the agents currently being explored for the treatment of advanced kidney cancer... - A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancerAndrew Artz
Department of Medicine, Section of Hematology/Oncology, University of Chicago, Pritzker School of Medicine, Chicago, Illinois 60637-1470, USA
Am J Clin Oncol 28:109-13. 2005.... - A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinomaAmy C Peterson
Department of Medicine, Section of Hematology/Oncology, The University of Chicago, USA
Invest New Drugs 24:141-9. 2006..CONCLUSIONS: The addition of Bryostatin-1 to IL-2 was well tolerated, but the overall response rate was low (3.2%), indicating that further studies with this combination are not warranted... - Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesotheliomaNick Pavlakis
Royal North Shore Hospital, Department of Medical Oncology, St Leonards, NSW 2065, Australia
Expert Opin Biol Ther 6:391-9. 2006..At present, a Phase III trial of doxorubicin with or without ranpirnase is nearing completion in MM patients without prior chemotherapy or one prior chemotherapy regimen... - Activities and accomplishments of the cancer and leukemia group B genitourinary committeeEric J Small
University of California San Francisco, San Francisco, California, USA
Clin Cancer Res 12:3596s-600s. 2006..In addition to these areas, future work of the committee will include further development of therapy for earlier-stage prostate cancer patients and bladder cancer patients... - Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancerJames O Jin
Section of Hematology Oncology, University of Chicago, IL 60637, USA
Clin Genitourin Cancer 5:150-4. 2006..Despite the general acceptance of gemcitabine/cisplatin in metastatic bladder cancer, its role and tolerability in the adjuvant setting, in which renal insufficiency is common, is unclear... - Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinomaChia Chi Lin
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
J Urol 177:84-9; discussion 89. 2007..We tested the efficacy and toxicity of adding paclitaxel to that regimen... - The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B TrialsSusan Halabi
Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27705, USA
J Urol 177:531-4. 2007.... - Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumorsRobert J Motzer
Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:247-56. 2007..Serum tumor marker decline during chemotherapy was assessed prospectively as a predictor of treatment outcome... - Systemic therapy for metastatic urothelial carcinomaChia-Chi Lin
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
BJU Int 101:795-803. 2008 - Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancerWalter M Stadler
University of Chicago, Illinois 60637, USA
J Urol 170:1141-5. 2003..To identify patient subgroups most likely to benefit and compare survival to that in previously described patient series long-term survival as a function of known and suspected prognostic variables was determined... - Impact of race on survival in men with metastatic hormone-refractory prostate cancerSusan Halabi
Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
Urology 64:212-7. 2004..71 to 1.02, P = 0.08) for blacks compared with whites. CONCLUSIONS: No statistically significant difference was found in overall survival between blacks and whites with metastatic hormone-refractory prostate cancer... - Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancerEric K Rowinsky
Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach Rd, 4th Floor, Zeller Building, San Antonio, TX 78229, USA
J Clin Oncol 22:3003-15. 2004.... - Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesotheliomaStanislaw M Mikulski
Alfacell Corp, 225 Belleville Ave, Bloomfield, NJ 07003, USA
J Clin Oncol 20:274-81. 2002..Patients with unresectable and histologically confirmed malignant mesothelioma (MM) were eligible... - Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancersCora N Sternberg
Department of Medical Oncology, San Camillo and Forlanini Hospitals, 00152, Rome, Italy
Crit Rev Oncol Hematol 46:S105-15. 2003..The molecular biology of these diseases is being unravelled and as knowledge accumulates, our ability to target these cancers will continue to increase... - Re: a multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesotheliomaNicholas J Vogelzang
Clin Lung Cancer 5:63-4. 2003 - Emerging insights into the biology and therapy of malignant mesotheliomaNicholas J Vogelzang
University of Chicago Cancer Research Center, Chicago, IL 60637, USA
Semin Oncol 29:35-42. 2002.... - Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium studyNancy B Davis
Section of Hematology/Oncology, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637, USA
J Clin Oncol 22:115-9. 2004..Insufficient biopsy and whole blood sample numbers preclude conclusions regarding proteasome inhibition within tumor. Further evaluation in this disease setting is not recommended... - A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinomaChristopher W Ryan
Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, Illinois, USA
Cancer 94:2602-9. 2002.... - Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibodyKenneth A Foon
Abgenix, Inc, Fremont, CA, USA
Int J Radiat Oncol Biol Phys 58:984-90. 2004..Therapy was generally well tolerated without statistically significant adverse events. Monoclonal antibody blockade of EGFR represents a new and exciting direction in cancer therapy... - Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesotheliomaNicholas J Vogelzang
University of Chicago, Cancer Research Center, 5841 South Maryland Ave, Chicago, IL 60637, USA
J Clin Oncol 21:2636-44. 2003..We conducted a phase III trial to determine whether treatment with pemetrexed and cisplatin results in survival time superior to that achieved with cisplatin alone... - The emerging role of antifolates in the treatment of malignant pleural mesotheliomaKarim Fizazi
Institut Gustave Roussy, Villejuif, France
Semin Oncol 29:77-81. 2002..In both trials, survival is the main endpoint. These trials will help to define the role of these new antifolates in malignant pleural mesothelioma... - Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicityChia-Chi Lin
Department of Oncology, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100, Taiwan
Cancer 106:1269-75. 2006..The excellent toxicity profile makes it a viable option for patients with poor general conditions. To reach any conclusion, randomized trials comparing P-HDFL with traditional cisplatin-based regimens are necessary... - Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical resultsBrian I Rini
University of California San Francisco, Comprehensive Cancer Center, San Francisco, CA 94115, USA
J Clin Oncol 20:2017-24. 2002..To evaluate the feasibility and safety of nonmyeloablative allogeneic stem-cell transplantation in patients with metastatic renal cell cancer (RCC) and to evaluate efficacy with respect to engraftment and tumor regression... - Future directions for gemcitabine in the treatment of genitourinary cancerNicholas J Vogelzang
Department of Medicine and Surgery (Urology, University of Chicago Cancer Research Center, Chicago, IL 60637-1470, USA
Semin Oncol 29:40-5. 2002..These data suggest the need for further trials of gemcitabine alone or in combinations in genitourinary cancer patients... - Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancerRichard L Schilsky
Department of Medicine, Section of Hematology Oncology, Cancer Research Center and Committee on Clinical Pharmacology, University of Chicago, Chicago, IL 60637, USA
J Clin Oncol 20:582-7. 2002..The goals of this phase I study were to determine the maximum-tolerated doses of capecitabine and gemcitabine in patients with advanced cancer and to describe the dose-limiting toxicities (DLT) and safety profile of this combination... - Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guidelineD Andrew Loblaw
American Society of Clinical Oncology, Alexandria, VA 22314, USA
J Clin Oncol 25:1596-605. 2007..To update the 2004 American Society of Clinical Oncology (ASCO) guideline on initial hormonal management of androgen-sensitive, metastatic, recurrent, or progressive prostate cancer (PCa)... - Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancerSusan Halabi
Department of Biostatistics and Bioinformatics and CALGB Statistical Center, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 21:1232-7. 2003..To develop and validate a model that can be used to predict the overall survival probability among metastatic hormone-refractory prostate cancer patients (HRPC)... - Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trialMichael A Carducci
Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD
J Clin Oncol 21:679-89. 2003..Quality of life was not adversely affected by atrasentan. CONCLUSION: Atrasentan is an oral, targeted therapy with favorable tolerability and the potential to delay progression of HRPCa... - Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activityBrian I Rini
Department of Medicine, Section of Hematology/Oncology, The University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, U.S.A
J Immunother (1997) 25:269-77. 2002.... - A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinomaApurva A Desai
Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
Cancer 95:1629-36. 2002.... - Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B studyEllis G Levine
Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263 0001, USA
Cancer 94:665-72. 2002.... - Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904Robert A Kratzke
Division of Hematology Oncology Transplant, The University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
J Thorac Oncol 3:417-21. 2008..This project (CALGB 159904) intended to test the hypothesis that in mesothelioma loss of p16INK4a via methylation would correlate with response to the cytidine analog and methylation inhibitor dihydro-5-azacytidine (DHAC)... - Pain predicts overall survival in men with metastatic castration-refractory prostate cancerSusan Halabi
Department of Biostatistics and Bioinformatics, Duke University, and Cancer and Leukemia Group B Statistical Center, Durham, NC, USA
J Clin Oncol 26:2544-9. 2008..The objective of this study was to determine whether men with CRPC who had higher pain interference scores at baseline had worse clinical outcomes compared with men who had lower pain scores... - Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancerH Barton Grossman
M.D. Anderson Cancer Center, Houston, USA
N Engl J Med 349:859-66. 2003.... - Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480Eric J Small
Comprehensive Cancer Center, University of California San Francisco, 1600 Devisadero Street, Third Floor, San Francisco, CA 94115, USA
J Clin Oncol 20:3369-75. 2002..To test the hypothesis that the efficacy and toxicity of suramin in the treatment of patients with hormone-refractory prostate cancer was dose dependent... - Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniquesSamuel G Armato
Department of Radiology, The University of Chicago, 5841 South Maryland Avenue, Chicago, Illinois 60637, USA
Med Phys 31:1105-15. 2004..93). We have developed computerized techniques for the measurement of mesothelioma tumor thickness in CT scans. These techniques achieved varying levels of agreement with measurements made by human observers... - Gene expression profiling of mesoblastic nephroma and Wilms tumors--comparison and clinical implicationsJun Sugimura
Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
Urology 64:362-8; discussion 368. 2004..CONCLUSIONS: The results of our study demonstrated that MN has a distinct gene expression profile and that some of the newly identified genes can be potentially used as novel diagnostic markers... - The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480Daniel J George
Divisions of Urology and Medical Oncology, Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham, NC 2771, USA
Clin Cancer Res 11:1815-20. 2005..In order to evaluate its prognostic significance in metastatic HRCaP patients, we measured IL-6 in plasma collected at baseline from patients in a large cooperative group study [Cancer and Leukemia Group B 9480 (CALGB 9480)]... - A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancerWalter M Stadler
University of Chicago Phase II Consortium, University of Chicago, Section of Hematology Oncology, Chicago, Illinois 60637, USA
Clin Cancer Res 10:3365-70. 2004..In vitro assessment of SU5416 on PSA secretion was assessed in the LNCaP cell line. Baseline serum basic fibroblast growth factor and plasma vascular endothelial growth factor (VEGF) were explored as prognostic factors... - Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)Eric J Small
UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Room A 718, San Francisco, CA 94115, USA
J Clin Oncol 22:1025-33. 2004..Thereafter, adrenal androgen ablation with agents such as ketoconazole (K) is commonly utilized. The therapeutic effect of AAWD alone was compared with simultaneous AAWD and K therapy... - Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 studyMary Ellen Taplin
Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Urology 66:386-91. 2005..Plasma CgA levels in patients with prostate cancer may reflect the extent of the tumor neuroendocrine phenotype... - Gene expression profiling of renal medullary carcinoma: potential clinical relevanceXiming J Yang
Department of Pathology, The University of Chicago, Chicago, Illinois, USA
Cancer 100:976-85. 2004..The genes that are expressed specifically in this tumor may lead to not only a better understanding of its molecular pathways and discoveries of novel diagnostic markers but also, more important, to effective therapeutic interventions... - Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scansSamuel G Armato
Department of Radiology, The University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA
Acad Radiol 12:1301-9. 2005..To evaluate the clinical acceptability of semiautomated methods for the measurement of mesothelioma tumor thickness in computed tomography (CT) scans... - A medical oncologist's approach to immunotherapy for advanced renal tumors: is nephrectomy indicated?Matthew M Cooney
Division of Hematology Oncology, University Hospitals of Cleveland, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA
Curr Urol Rep 5:19-24. 2004..Even with this aggressive approach, most patients eventually will die from their kidney cancer; therefore, every patient with metastatic disease should be considered for enrollment into clinical trials... - American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancerD Andrew Loblaw
Cancer Policy and Clinical Affairs, 1900 Duke St, Suite 200, Alexandria, VA 22314, USA
J Clin Oncol 22:2927-41. 2004..The focus of this document is on the use, combinations, and timing of various forms of androgen deprivation therapy (ADT) for the palliation of men with androgen-sensitive disease... - A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813William K Oh
Lank Center for Geritourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer 98:2592-8. 2003..The authors determined the safety and efficacy of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor (G-CSF) support in patients with hormone-refractory prostate carcinoma... - Variability in mesothelioma tumor response classificationSamuel G Armato
Department of Radiology, The University of Chicago, 5841 S Maryland Ave, Chicago, IL 60637, USA
AJR Am J Roentgenol 186:1000-6. 2006..In addition, the performance of a semiautomated measurement method was evaluated... - Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480Peter A Humphrey
Washington University Medical Center, St Louis, MO 63110, USA
Clin Genitourin Cancer 4:269-74. 2006..Scatter factor, also known as hepatocyte growth factor (SF/HGF), is a polypeptide growth factor thought to be important in the growth and spread of prostatic carcinoma... - Molecular subclassification of kidney tumors and the discovery of new diagnostic markersMasayuki Takahashi
Laboratory of Cancer Genetics, Van Andel Research Institute, 333 Bostwick NE, Grand Rapids, MI 49503, USA
Oncogene 22:6810-8. 2003..We have also identified in these subtypes differentially expressed genes that could have important diagnostic and therapeutic implications... - Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studiesSusan Halabi
Department of Biostatistics and Bioinformatics, Duke University Medical Center, 2424 Erwin Road, Durham, NC 27705, USA
J Urol 176:81-6. 2006..We determined if age is a prognostic factor of clinical outcomes, specifically overall survival, disease-free survival and progression-free survival in men with hormone refractory prostate cancer... - Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignanciesChristopher W Ryan
Section of Hematology Oncology, Department of Medicine, Cancer Research Center, and Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, and Abbott Laboratories, Abbott Park, Illinois, USA
Clin Cancer Res 10:4406-11. 2004..This Phase I study sought to determine the toxicity and pharmacokinetics of daily atrasentan in a population of both female and male subjects with advanced malignancies...